A major role of TWEAK/Fn14 axis as a therapeutic target for post-angioplasty restenosis

被引:21
|
作者
Mendez-Barbero, Nerea [1 ]
Gutierrez-Munoz, Carmen [1 ]
Madrigal-Matute, Julio [2 ]
Minguez, Pablo [3 ]
Egido, Jesus [4 ]
Michel, Jean-Baptiste [5 ]
Martin-Ventura, Jose L. [1 ]
Esteban, Vanesa [6 ,7 ]
Blanco-Colio, Luis M. [1 ]
机构
[1] IIS Fdn Jimenez Diaz, Vasc Res Lab, CIBERCV, Madrid, Spain
[2] Albert Einstein Coll Med, Dept Dev & Mol Biol, New York, NY USA
[3] IIS Fdn Jimenez Diaz, Dept Genet & Genom, Madrid, Spain
[4] IIS Fdn Jimenez Diaz, Renal & Diabet Res Lab, CIBERDEM, Madrid, Spain
[5] INSERM, U1148, LVTS, Paris, France
[6] IIS Fdn Jimenez Diaz, Dept Immunol, Madrid, Spain
[7] IIS Fdn Jimenez Diaz, ARADyAL, Madrid, Spain
来源
EBIOMEDICINE | 2019年 / 46卷
关键词
Restenosis; Proliferation; Cyclins; TWEAK; Fn14; SMOOTH-MUSCLE-CELLS; NEOINTIMAL FORMATION; ATHEROSCLEROSIS; PROLIFERATION; REGULATOR; INJURY; FN14; PATHWAY; FAMILY; GROWTH;
D O I
10.1016/j.ebiom.2019.07.072
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Tumor necrosis factor-like weak inducer of apoptosis (Tnfsf12; TWEAK) and its receptor Fibroblast growth factor-inducible 14 (Tnfrsf12a; Fn14) participate in the inflammatory response associated with vascular remodeling. However, the functional effect of TWEAK on vascular smooth muscle cells (VSMCs) is not completely elucidated. Methods: Next generation sequencing-based methods were performed to identify genes and pathways regulated by TWEAK in VSMCs. Flow-citometry, wound-healing scratch experiments and transwell migration assays were used to analyze VSMCs proliferation and migration. Mouse wire injury model was done to evaluate the role of TWEAK/Fn14 during neointimal hyperplasia. Findings: TWEAK up-regulated 1611 and down-regulated 1091 genes in VSMCs. Using a gene-set enrichment method, we found a functional module involved in cell proliferation defined as the minimal network connecting top TWEAK up-regulated genes. In vitro experiments in wild-type or Tnfrsf12a deficient VSMCs demonstrated that TWEAK increased cell proliferation, VSMCs motility and migration. Mechanistically, TWEAK increased cyclins (cyclinD1), cyclin-dependent kinases (CDK4, CDK6) and decreased cydin-dependent kinase inhibitors (p15(INK4B)) mRNA and protein expression. Downregulation of p15(INK)(4B) induced by TWEAK was mediated by mitogen-activated protein kinase ERK and Akt activation. Tnfrsf12a or Tnfsf12 genetic depletion and pharmacological intervention with TWEAK blocking antibody reduced neointimal formation, decreasing cell proliferation, cydin Dl and CDK4/6 expression, and increasing p15(INK4B) expression compared with wild type or IgG-treated mice in wire-injured femoral arteries. Finally, immunohistochemistry in human coronary arteries with stenosis or in-stent restenosis revealed high levels of Fn14, TWEAK and PCNA in VSMCs enriched areas of the neointima as compared with healthy coronary arteries. Interpretation: Our data define a major role of TWEAK/Fn14 in the control of VSMCs proliferation and migration during neointimal hyperplasia after wire injury in mice, and identify TWEAK/Fn14 as a potential target for treating in-stent restenosis. (C) 2019 Published by Elsevier B.V.
引用
收藏
页码:274 / 289
页数:16
相关论文
共 50 条
  • [1] A Major Role for TWEAK as a Therapeutic Target in Post Angioplasty Restenosis
    Mendez-Barbero, Nerea
    Gutierrez-Munoz, Carmen
    Madrigal-Matute, Julio
    Minguez, Pablo
    Egido, Jesus
    Martin-Ventura, Jose Luis
    Esteban, Vanesa
    Blanco-Colio, Luis Miguel
    [J]. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY, 2019, 39
  • [2] TWEAK/Fn14 axis in respiratory diseases
    Wang, Min
    Xie, Zhijuan
    Xu, Jin
    Feng, Zhuyu
    [J]. CLINICA CHIMICA ACTA, 2020, 509 : 139 - 148
  • [3] The TWEAK/FN14 axis in cardiomyocyte proliferation
    Novoyatleva, T.
    Diehl, F.
    Van Amerongen, M. J.
    Patra, C.
    Ferrazzi, F.
    Engel, F. B.
    [J]. EUROPEAN JOURNAL OF CELL BIOLOGY, 2010, 89 : 62 - 62
  • [4] The TWEAK/Fn14 axis in anaphylactic shock
    Galli, Stephen J.
    [J]. JOURNAL OF ALLERGY AND CLINICAL IMMUNOLOGY, 2020, 145 (02) : 491 - 493
  • [5] TWEAK/Fn14 axis: a promising target for the treatment of cardiovascular diseases
    Blanco-Colio, Luis M.
    [J]. FRONTIERS IN IMMUNOLOGY, 2014, 5
  • [6] The TWEAK/Fn14 as a novel therapeutic target for cutaneous lupus erythematosus
    Friedman, Adam
    Putterman, Chaim
    Blecher, Karin
    Xia, Yumin
    [J]. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2012, 66 (04) : AB134 - AB134
  • [7] TWEAK/Fn14, a pathway and novel therapeutic target in myotonic dystrophy
    Yadava, Ramesh S.
    Foff, Erin P.
    Yu, Qing
    Gladman, Jordan T.
    Kim, Yun K.
    Bhatt, Kirti S.
    Thornton, Charles A.
    Zheng, Timothy S.
    Mahadevan, Mani S.
    [J]. HUMAN MOLECULAR GENETICS, 2015, 24 (07) : 2035 - 2048
  • [8] The TWEAK Receptor Fn14 Is a Therapeutic Target in Melanoma: Immunotoxins Targeting Fn14 Receptor for Malignant Melanoma Treatment
    Zhou, Hong
    Ekmekcioglu, Suhendan
    Marks, John W.
    Mohannedali, Khalid A.
    Asrani, Kaushal
    Phillips, Keeley K.
    Brown, Sharron A. N.
    Cheng, Emily
    Weiss, Michele B.
    Hittelman, Walter N.
    Tran, Nhan L.
    Yagita, Hideo
    Winkles, Jeffrey A.
    Rosenblum, Michael G.
    [J]. JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2013, 133 (04) : 1052 - 1062
  • [9] The TWEAK–Fn14 cytokine–receptor axis: discovery, biology and therapeutic targeting
    Jeffrey A. Winkles
    [J]. Nature Reviews Drug Discovery, 2008, 7 : 411 - 425
  • [10] TWEAK/Fn14 axis is an important player in fibrosis
    Zhang, Yitian
    Zeng, Weihui
    Xia, Yumin
    [J]. JOURNAL OF CELLULAR PHYSIOLOGY, 2021, 236 (05) : 3304 - 3316